What is Sense Neuro Diagnostics?
Sense Neuro Diagnostics is a pioneering medical technology firm dedicated to enhancing patient outcomes for individuals suffering from stroke and brain injuries. The company is at the forefront of developing non-invasive technologies designed for the rapid detection and effective triage of neurological conditions. Their innovative solutions aim to provide continuous, real-time monitoring of intracranial hemorrhage and swift identification of critical stroke subtypes, including ischemic stroke with large vessel occlusion, ischemic stroke without large vessel occlusion, and intracerebral hemorrhage. Sense Neuro Diagnostics is actively engaged in a pivotal trial for its continuous intracranial hemorrhage monitoring system and has successfully completed a first-in-human pilot study for its triage technology.
How much funding has Sense Neuro Diagnostics raised?
Sense Neuro Diagnostics has raised a total of $1.6M across 3 funding rounds:
Private Equity
$250K
Private Equity
$1.3M
Debt
$76K
Private Equity (2017): $250K with participation from Accelerant
Private Equity (2017): $1.3M led by Queen City Angels
Debt (2021): $76K supported by PPP
Key Investors in Sense Neuro Diagnostics
Accelerant
Accelerant Dayton is a digital agency with 12 years of experience and a team of 15 employees, specializing in SEO consultancy, site optimization, and user retention strategies. They cater to Fortune 5000 clients, providing tailored solutions that enhance online visibility and drive organic traffic.
Queen City Angels
QCA Ventures is an investor network focused on supporting entrepreneurs and early stage companies. It helps founders access funding, mentorship, and experienced guidance, and it engages investors through member programs, events, and deal sourcing.
PPP
Public-Private Partnership
What's next for Sense Neuro Diagnostics?
The recent influx of substantial expansion capital positions Sense Neuro Diagnostics for significant growth and market penetration. This strategic investment is expected to accelerate the company's ongoing pivotal trial for continuous intracranial hemorrhage monitoring and further develop its promising triage technology. The enterprise-level funding suggests a mature stage of development, likely enabling broader clinical adoption and commercialization efforts, solidifying its role in advancing neurological diagnostics and patient care.
See full Sense Neuro Diagnostics company page
